Landmark 14 · Discovery
Extra copies of the synuclein gene cause Parkinson's
In short
Simply having too much normal alpha-synuclein is enough to cause Parkinson's, the main reason for trying to lower it.
- What it is
- Discovery
- Outcome
- Confirmed and built on
- When
- 2003
- Approach
- Clear the bad protein
- Research lane
- Synuclein lowering
- Last checked
- 19 Oct 2026
The research record
This is the project's file for this landmark, as written and checked. Sources are listed at the end; anything not yet confirmed is marked "Not yet verified".
Who
Andrew Singleton (National Institute on Aging, Bethesda), Matthew Farrer, John Hardy, Katrina Gwinn-Hardy and 18 co-authors (22 in all). Funders were not checked.
What happened
In a large family (the Iowa kindred, named in the authors' later clinical report) with dominantly inherited Parkinson's and no SNCA point mutation, linkage mapping placed the disease region on chromosome 4 around SNCA. Quantitative PCR and FISH showed the region is triplicated (about 2 Mbp, 17 genes), and the extra gene dose was judged the most likely explanation. Science 302:841, 31 October 2003. In 2004 two papers in The Lancet found whole-gene duplications (two copies instead of three) in families with a milder, more typical Parkinson's: one French family (Chartier-Harlin et al.) and two patients (Ibáñez et al.), showing a dose effect. This differs from landmark 4, where a changed protein caused disease; here the protein is normal but there is too much of it.
Why it moved us toward a cure
It is the main rationale for lowering alpha-synuclein by any route: antisense drugs, antibodies or other methods.
Outcome
Advanced. Synuclein-lowering strategies are in trials, but none has shown a clinical benefit yet.
Sources
- Singleton et al., Science 2003, DOI 10.1126/science.1090278
- Alzforum, "Synuclein and Parkinson's – It's All in the Dose"
- Chartier-Harlin et al., Lancet 2004;364:1167–1169, DOI 10.1016/S0140-6736(04)17103-1, PMID 15451224 · Ibáñez et al., Lancet 2004;364:1169–1171, DOI 10.1016/S0140-6736(04)17104-3, PMID 15451225
- Gwinn et al., Mov Disord 2011;26:2134–2136, DOI 10.1002/mds.23776, PMID 21656851 ("Iowa kindred")
- Not yet verified: that the Science family is the same kindred as in Gwinn 2011 (title and shared authors say so; the Science text was not read); the family's size; the linkage, qPCR and FISH methods (from the earlier text; Science has no abstract and Alzforum was not checked for them).
How it connects
Built on
- builds on First Parkinson's gene: SNCA · 1997
Led to
- builds on SNCA duplications: ordinary-looking Parkinson's, partial penetrance · 2004
- builds on SNCA Rep1 promoter variant raises risk · 2006
- builds on Too little synuclein harms neurons · 2010
- builds on Patient-derived dopamine neurons · 2011
- builds on A risk variant that regulates SNCA · 2016
- builds on β2 agonists lower SNCA · 2017
- builds on Gene editing of SNCA · 2018
- tests ION464 / BIIB101 (synuclein antisense) · 2022
- tests Synuclein-lowering drugs (overview) · 2022
- tests Buntanetap Phase 3 · 2024 (link inferred)
- tests LY3962681 (Lilly siRNA) · 2024
- tests ALN-SNCA (Regeneron siRNA) · 2025